{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T02:40:56Z","timestamp":1794624056450,"version":"4.9.1"},"reference-count":67,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000927","name":"Prostate Cancer Foundation of Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000927","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011371","name":"Royal Australasian College of Surgeons","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011371","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.eururo.2019.01.049","type":"journal-article","created":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T19:08:04Z","timestamp":1550171284000},"page":"403-417","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":872,"title":["Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer\u2014Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"77","author":[{"given":"Marlon","family":"Perera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Papa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Udovicich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Vela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Christidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Bolton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Lawrentschuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan G.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2019.01.049_bib0345","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eururo.2019.01.049_bib0350","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.eururo.2014.09.004","article-title":"Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature","volume":"67","author":"Ost","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.01.049_bib0355","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2019.01.049_bib0360","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.eururo.2018.06.004","article-title":"Stereotactic ablative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial","volume":"74","author":"Siva","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.01.049_bib0365","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.eururo.2018.10.041","article-title":"Salvage lymph node dissection for nodal recurrent prostate cancer: a systematic review","volume":"76","author":"Ploussard","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.01.049_bib0370","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrurol.2016.26","article-title":"Current use of PSMA-PET in prostate cancer management","volume":"13","author":"Maurer","year":"2016","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2019.01.049_bib0375","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2019.01.049_bib0380","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S","article-title":"Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases","volume":"82","author":"Bostwick","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2019.01.049_bib0385","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","article-title":"PET imaging with a [Ga-68]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions","volume":"40","author":"Afshar-Oromieh","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2019.01.049_bib0390","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.eururo.2018.03.030","article-title":"Impact of (68)Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis","volume":"74","author":"Han","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.01.049_bib0395","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","article-title":"Sensitivity, specificity, and predictors of positive Ga-68-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis","volume":"70","author":"Perera","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.01.049_bib0400","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","volume":"70","author":"Papa","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.01.049_bib0405","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2019.01.049_bib0410","series-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2008"},{"key":"10.1016\/j.eururo.2019.01.049_bib0415","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eururo.2019.01.049_bib0420","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/2049-3258-72-39","article-title":"a Stata command to perform meta-analysis of binomial data","volume":"72","author":"Nyaga","year":"2014","journal-title":"Arch Public Health"},{"key":"10.1016\/j.eururo.2019.01.049_bib0425","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/jech-2013-203104","article-title":"Meta-analysis of prevalence","volume":"67","author":"Barendregt","year":"2013","journal-title":"J Epidemiol Commun Health"},{"key":"10.1016\/j.eururo.2019.01.049_bib0430","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2019.01.049_bib0435","series-title":"midas: A program for meta-analytical integration of diagnostic accuracy studies in Stata","author":"Dwamena","year":"2007"},{"key":"10.1016\/j.eururo.2019.01.049_bib0440","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/bju.14374","article-title":"A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET\/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol","volume":"122","author":"Hofman","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2019.01.049_bib0445","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.crad.2007.05.022","article-title":"The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis","volume":"63","author":"Hovels","year":"2008","journal-title":"Clin Radiol"},{"key":"10.1016\/j.eururo.2019.01.049_bib0450","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.eururo.2012.09.039","article-title":"Utility of choline positron emission tomography\/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis","volume":"63","author":"Evangelista","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.01.049_bib0455","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1007\/s00259-016-3366-9","article-title":"Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with Ga-68-PSMA-HBED-CC than with F-18-fluoroethylcholine PET\/CT","volume":"43","author":"Pfister","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2019.01.049_bib0460","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.eururo.2015.12.053","article-title":"Simultaneous Ga-PSMA HBED-CC PET\/MRI improves the localization of primary prostate cancer","volume":"70","author":"Eiber","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.01.049_bib0465","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000484695","article-title":"Integrated (68)Gallium labelled prostate-specific membrane antigen-11 positron emission tomography\/magnetic resonance imaging enhances discriminatory power of multi-parametric prostate magnetic resonance imaging","volume":"100","author":"Al-Bayati","year":"2018","journal-title":"Urol Int"},{"key":"10.1016\/j.eururo.2019.01.049_bib0470","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.juro.2018.01.079","article-title":"68Ga-PSMA positron emission tomography\/computerized tomography for primary diagnosis of prostate cancer in men with contraindications to or negative multiparametric magnetic resonance imaging mpMRI: a prospective observational study","volume":"200","author":"Lopci","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.01.049_bib0475","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00259-018-4160-7","article-title":"Improved specificity with (68)Ga PSMA PET\/CT to detect clinically significant lesions \u201cinvisible\u201d on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology","volume":"46","author":"Donato","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2019.01.049_bib0480","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nrurol.2016.177","article-title":"An update on focal therapy for prostate cancer","volume":"13","author":"Perera","year":"2016","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2019.01.049_bib0485","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eururo.2017.02.036","article-title":"\u201cGotta catch \u2018em all\u201d, or do we? Pokemet approach to metastatic prostate cancer","volume":"72","author":"Murphy","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.01.049_bib0490","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/cpf.12480","article-title":"68 Ga-PSMA PET\/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature","volume":"38","author":"Zacho","year":"2018","journal-title":"Clin Physiol Funct Imaging"},{"key":"10.1016\/j.eururo.2019.01.049_bib0495","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2967\/jnumed.117.192625","article-title":"Impact of Ga-68-prostate-specific membrane antigen PET\/CT on prostate cancer management","volume":"59","author":"Afaq","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2019.01.049_bib0500","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s00259-017-3711-7","article-title":"Diagnostic performance of Ga-68-PSMA-11 (HBED-CC) PET\/CT in patients with recurrent prostate cancer: evaluation in 1007 patients","volume":"44","author":"Afshar-Oromieh","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2019.01.049_bib0505","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s00259-016-3572-5","article-title":"Detection rate of PET\/CT in patients with biochemical relapse of prostate cancer using [Ga-68]PSMA I&T and comparison with published data of [Ga-68]PSMA HBED-CC","volume":"44","author":"Berliner","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2019.01.049_bib0510","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13550-016-0233-4","article-title":"Impact of Ga-68-PSMA PET\/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy","volume":"6","author":"Bluemel","year":"2016","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.eururo.2019.01.049_bib0515","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.eururo.2015.06.010","article-title":"Initial experience of Ga-68-PSMA PET\/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy","volume":"69","author":"Budaeus","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.01.049_bib0520","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.radonc.2017.10.022","article-title":"Delineating sites of failure following post-prostatectomy radiation treatment using Ga-68-PSMA-PET","volume":"126","author":"Byrne","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.eururo.2019.01.049_bib0525","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.2967\/jnumed.118.209387","article-title":"Potential impact of 68Ga-PSMA-11 PET\/CT on prostate cancer definitive radiation therapy planning","volume":"59","author":"Calais","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2019.01.049_bib0530","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1007\/s00259-015-3078-6","article-title":"Ga-68-PSMA PET\/CT for restaging recurrent prostate cancer: which factors are associated with PET\/CT detection rate?","volume":"42","author":"Ceci","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2019.01.049_bib0535","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/pros.22956","article-title":"Prostate-specific membrane antigen-based imaging in prostate cancer: impact on clinical decision making process","volume":"75","author":"Demirkol","year":"2015","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2019.01.049_bib0540","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13014-016-0646-2","article-title":"Integration of Ga-68-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study","volume":"11","author":"Dewes","year":"2016","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.eururo.2019.01.049_bib0545","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s11307-015-0866-0","article-title":"Comparison of [F-18]DCFPyL and [Ga-68]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer","volume":"17","author":"Dietlein","year":"2015","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.eururo.2019.01.049_bib0550","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2967\/jnumed.115.154153","article-title":"Evaluation of hybrid Ga-68-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy","volume":"56","author":"Eiber","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2019.01.049_bib0555","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.2967\/jnumed.116.184457","article-title":"Detection efficacy of hybrid Ga-68-PSMA ligand PET\/CT in prostate cancer patients with biochemical recurrence after primary radiation therapy defined by Phoenix criteria","volume":"58","author":"Einspieler","year":"2017","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.eururo.2019.01.049_bib0560","doi-asserted-by":"crossref","first-page":"e1313","DOI":"10.1016\/S1569-9056(18)31753-6","article-title":"Staging performance and clinical impact of 68Ga-PSMA 11 ligand PET\/MRI for primary diagnosed prostate cancer. Presented at: 33rd Annual European Association of Urology Congress, EAU, Denmark","volume":"17","author":"Grubmuller","year":"2018","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.eururo.2019.01.049_bib0565","doi-asserted-by":"crossref","first-page":"186","DOI":"10.4103\/1450-1147.207272","article-title":"A comparative study of 68Gallium-prostate specific membrane antigen positron emission tomography-computed tomography and magnetic resonance imaging for lymph node staging in high risk prostate cancer patients: an initial experience","volume":"16","author":"Gupta","year":"2017","journal-title":"World J Nucl Med"},{"key":"10.1016\/j.eururo.2019.01.049_bib0570","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ijrobp.2017.06.2448","article-title":"Prostate-specific membrane antigen positron emission tomography-computed tomography for prostate cancer: distribution of disease and implications for radiation therapy planning","volume":"99","author":"Gupta","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2019.01.049_bib0575","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/pros.23347","article-title":"Ga-68-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: individualized medicine or new standard in salvage treatment","volume":"77","author":"Habl","year":"2017","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2019.01.049_bib0580","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00066-017-1231-9","article-title":"Patterns of relapse as determined by Ga-68-PSMA ligand PET\/CT after radical prostatectomy: importance for tailoring and individualizing treatment","volume":"194","author":"Henkenberens","year":"2018","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.eururo.2019.01.049_bib0585","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.radonc.2016.11.023","article-title":"Delineating biochemical failure with Ga-68-PSMA-PET following definitive external beam radiation treatment for prostate cancer","volume":"122","author":"Hruby","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.eururo.2019.01.049_bib0590","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/MNM.0000000000000617","article-title":"The role of PSMA PET\/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels","volume":"38","author":"Kabasakal","year":"2017","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.eururo.2019.01.049_bib0595","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00259-017-3850-x","article-title":"Clinical performance of Ga-68-PSMA-11 PET\/MRI for the detection of recurrent prostate cancer following radical prostatectomy","volume":"45","author":"Kranzbuhler","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2019.01.049_bib0600","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13550-017-0327-7","article-title":"Optimal MRI sequences for Ga-68-PSMA-11 PET\/MRI in evaluation of biochemically recurrent prostate cancer","volume":"7","author":"Lake","year":"2017","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.eururo.2019.01.049_bib0605","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/MNM.0000000000000791","article-title":"Ga-68-PSMA-HBED-CC PET\/CT imaging in black versus white South African patients with prostate carcinoma presenting with a low volume, androgen-dependent biochemical recurrence: a prospective study","volume":"39","author":"Lengana","year":"2018","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.eururo.2019.01.049_bib0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2015.02.2118","article-title":"Preoperative lymph node staging in intermediate to high-risk prostate cancer patients using 68Ga-HBED-PSMA PET hybrid imaging\u2014a patient- and field-based analysis","volume":"193","author":"Maurer","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.01.049_bib0615","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/bju.13616","article-title":"The use of (68) Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer","volume":"118","author":"Meredith","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2019.01.049_bib0620","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1007\/s00259-017-3752-y","article-title":"The accuracy of Ga-68-PSMA PET\/CT in primary lymph node staging in high-risk prostate cancer","volume":"44","author":"Obek","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2019.01.049_bib0625","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2967\/jnumed.117.197160","article-title":"The impact of Ga-68-PSMA PET\/CT on management intent in prostate cancer: results of an Australian prospective multicenter study","volume":"59","author":"Roach","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2019.01.049_bib0630","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s12149-017-1207-y","article-title":"Relationships between serum PSA levels. Gleason scores and results of 68Ga-PSMAPET\/CT in patients with recurrent prostate cancer","volume":"31","author":"Sanli","year":"2017","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.eururo.2019.01.049_bib0635","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1007\/s00259-015-3302-4","article-title":"Ga-68-PSMA-11 dynamic PET\/CT imaging in biochemical relapse of prostate cancer","volume":"43","author":"Sachpekidis","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2019.01.049_bib0640","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1007\/s00259-015-3251-y","article-title":"Biphasic Ga-68-PSMA-HBED-CC-PET\/CT in patients with recurrent and high-risk prostate carcinoma","volume":"43","author":"Sahlmann","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2019.01.049_bib0645","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1007\/s00259-017-3669-5","article-title":"Comparison of standard and delayed imaging to improve the detection rate of [Ga-68]PSMA I&T PET\/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer","volume":"44","author":"Schmuck","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2019.01.049_bib0650","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s00259-016-3490-6","article-title":"Comparison of Ga-68-labelled PSMA-11 and C-11-choline in the detection of prostate cancer metastases by PET\/CT","volume":"44","author":"Schwenck","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2019.01.049_bib0655","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s00259-015-3188-1","article-title":"Ga-68-PSMA-11 PET\/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients","volume":"43","author":"Sterzing","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2019.01.049_bib0660","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/bju.13397","article-title":"Ga-68-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment","volume":"117","author":"van Leeuwen","year":"2016","journal-title":"BJU Int"},{"issue":"4 Suppl. 1","key":"10.1016\/j.eururo.2019.01.049_bib0665","first-page":"e1038","article-title":"Prospective evaluation of 68GA-PSMA positron emission tomography\/computerized tomography for preoperative lymph node staging in prostate cancer, Presented at: 2016 Annual Meeting of the American Urological Association, AUA, San Diego, CA, USA","volume":"195","author":"Van Leeuwen","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.01.049_bib0670","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00259-015-3240-1","article-title":"Extent of disease in recurrent prostate cancer determined by [Ga-68]PSMA-HBED-CC PET\/CT in relation to PSA levels. PSA doubling time and Gleason score","volume":"43","author":"Verburg","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2019.01.049_bib0675","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12967-017-1333-2","article-title":"Comparison of Ga-68-PSMA-11 PET-CT with mpMRI for preoperative lymph node staging in patients with intermediate to high-risk prostate cancer","volume":"15","author":"Zhang","year":"2017","journal-title":"J Transl Med"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283819300958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283819300958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:05:56Z","timestamp":1759583156000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283819300958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":67,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0302283819300958"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2019.01.049","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer\u2014Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2019.01.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}